KTRA
Kintara Therapeutics Inc
Halal Rating :
Last Price
$4.73
Last updated:
Market Cap
-
7D Change
9.74%
1 Year Change
3598.2%
Company Overview
Industries
Exchange
Next Earnings Date
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapies. The company's primary focus is on developing two late-stage, Phase 3-ready therapeutics: VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Kintara Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.